TY -的T1 meropen的有效性和安全性em/clavulanate-containing regimens in the treatment of MDR- and XDR-TB JF - European Respiratory Journal JO - Eur Respir J SP - 1235 LP - 1243 DO - 10.1183/13993003.02146-2015 VL - 47 IS - 4 AU - Tiberi, Simon AU - Payen, Marie-Christine AU - Sotgiu, Giovanni AU - D'Ambrosio, Lia AU - Alarcon Guizado, Valentina AU - Alffenaar, Jan Willem AU - Abdo Arbex, Marcos AU - Caminero, Jose A. AU - Centis, Rosella AU - De Lorenzo, Saverio AU - Gaga, Mina AU - Gualano, Gina AU - Roby Arias, Aurora Jazmín AU - Scardigli, Anna AU - Skrahina, Alena AU - Solovic, Ivan AU - Sulis, Giorgia AU - Tadolini, Marina AU - Akkerman, Onno W. AU - Alarcon Arrascue, Edith AU - Aleska, Alena AU - Avchinko, Vera AU - Bonini, Eduardo Henrique AU - Chong Marín, Félix Antonio AU - Collahuazo López, Lorena AU - de Vries, Gerard AU - Dore, Simone AU - Kunst, Heinke AU - Matteelli, Alberto AU - Moschos, Charalampos AU - Palmieri, Fabrizio AU - Papavasileiou, Apostolos AU - Spanevello, Antonio AU - Vargas Vasquez, Dante AU - Viggiani, Pietro AU - White, Veronica AU - Zumla, Alimuddin AU - Migliori, Giovanni Battista Y1 - 2016/04/01 UR - //www.qdcxjkg.com/content/47/4/1235.abstract N2 - No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases.Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6–9) versus 5 (4–6)). Patients were treated with a meropenem/clavulanate-containing regimen for a median (IQR) of 85 (49–156) days.No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment).The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/clavulanate could be active in treating MDR- and XDR-TB cases.Meropenem/clavulanate is effective and safe to treat MDR- and XDR-TB in comparison with controls http://ow.ly/XG75j ER -